No Data
FUSEN PHARM (01652) announced its 2024 performance, with losses attributable to equity holders amounting to approximately 0.189 billion yuan, an increase of about 4.2 times year-on-year.
FUSEN PHARM (01652) announced its performance for 2024, with revenue of approximately 0.326 billion yuan, a year-on-year decrease of about 42.4...
Express News | Fusen Pharmaceutical FY Gross Margin 49.9%
Express News | Fusen Pharmaceutical FY Revenue RMB 326 Million
FUSEN PHARM: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024
The optimization policy direction for drug central purchasing is a hot topic: overcoming the "Low Stock Price" phenomenon and guiding quality supervision.
① The government work report on March 5 mentioned the need to "optimize the Pharmaceutical and consumables centralized procurement policy"; ② From the overall trend of optimizing the centralized procurement policy, there is a greater emphasis on moderate price reductions and quality supervision, and the concentration of the Industry is expected to further increase.
BD Trade resolves financing difficulties! Industry: Innovative Drugs have survived, but the challenge of thriving is even greater.
① In 2024, license-out Trade has become an important way for Biotech to recover funds and increase revenue; ② The quality and standing of Innovative Drugs in China are gaining more international recognition; ③ Whether Innovative Drugs are worth investing in is related to the secondary market in the short term, but in the medium to long term, it depends on the improvement of the primary market exit channels, the payment environment for Innovative Drugs, and other issues.
